Quantum BioPharma Ltd. Profit Loss Attributable To Noncontrolling Interests
Quantum BioPharma Ltd. (QNTM) reported Profit Loss Attributable To Noncontrolling Interests of -$26.96 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Notes
ifrs-full:ProfitLossAttributableToNoncontrollingInterests · last filed 2026-03-26
- Quantum BioPharma Ltd. profit loss attributable to noncontrolling interests for the quarter ending 2025-12-31 was -$3.70M.
- Quantum BioPharma Ltd. profit loss attributable to noncontrolling interests for the quarter ending 2025-09-30 was -$4.75M.
- Quantum BioPharma Ltd. profit loss attributable to noncontrolling interests for the quarter ending 2025-06-30 was -$9.77M.
- Quantum BioPharma Ltd. profit loss attributable to noncontrolling interests for the quarter ending 2025-03-31 was -$8.74M.
| Period end | Profit Loss Attributable To Noncontrolling Interests 3 month | Profit Loss Attributable To Noncontrolling Interests 3 month as first filed | Profit Loss Attributable To Noncontrolling Interests 6 month | Profit Loss Attributable To Noncontrolling Interests 9 month | Profit Loss Attributable To Noncontrolling Interests 9 month as first filed | Profit Loss Attributable To Noncontrolling Interests 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$3.70M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$8.45M derived: sum of 2 quarters · filed 2026-03-26 | -$18.22M derived: sum of 3 quarters · filed 2026-03-26 | -$26.96M 20-F · filed 2026-03-26 | ||
| 2025-09-30 | -$4.75M 6-K · filed 2025-11-06 | -$14.51M derived: sum of 2 quarters · filed 2025-11-06 | -$23.25M 6-K · filed 2025-11-06 | -$28.71M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2025-06-30 | -$9.77M 6-K · filed 2025-08-07 | -$18.51M 6-K · filed 2025-08-07 | -$23.96M derived: sum of 3 quarters · filed 2026-03-26 | -$27.98M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2025-03-31 | -$8.74M 6-K/A · filed 2025-06-16 | -$14.20M derived: sum of 2 quarters · filed 2026-03-26 | -$18.21M derived: sum of 3 quarters · filed 2026-03-26 | -$21.56M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2024-12-31 | -$5.46M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$9.47M derived: sum of 2 quarters · filed 2026-03-26 | -$12.82M derived: sum of 3 quarters · filed 2026-03-26 | -$14.92M 20-F · filed 2026-03-26 | ||
| 2024-09-30 | -$4.02M 6-K · filed 2025-11-06 | -$188.16K 6-K · filed 2024-11-12 | -$7.37M derived: sum of 2 quarters · filed 2025-11-06 | -$9.46M 6-K · filed 2025-11-06 | -$616.79K 6-K · filed 2024-11-12 | -$27.62M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-06-30 | -$3.35M 6-K · filed 2025-08-07 | -$5.44M 6-K · filed 2025-08-07 | -$23.60M derived: sum of 3 quarters · filed 2026-03-26 | -$23.67M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2024-03-31 | -$2.09M 6-K/A · filed 2025-06-16 | -$20.25M derived: sum of 2 quarters · filed 2026-03-26 | -$20.32M derived: sum of 3 quarters · filed 2026-03-26 | -$25.81M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2023-12-31 | -$18.16M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-26 | -$18.23M derived: sum of 2 quarters · filed 2026-03-26 | -$23.72M derived: sum of 3 quarters · filed 2026-03-26 | -$18.23M 20-F · filed 2026-03-26 | ||
| 2023-09-30 | -$71.36K 6-K · filed 2024-11-12 | -$5.56M derived: sum of 2 quarters · filed 2024-11-12 | -$71.36K 6-K · filed 2024-11-12 | |||
| 2023-06-30 | -$5.49M 6-K/A · filed 2024-08-19 | -$15.45M 6-K/A · filed 2024-08-19 | ||||
| 2022-12-31 | -$23.61M 20-F/A · filed 2025-03-31 | |||||
| 2021-12-31 | -$35.29M 20-F · filed 2024-04-02 |